KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 123 filers reported holding KEROS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,755,760 | -29.6% | 902,000 | -11.2% | 0.00% | 0.0% |
| Q2 2023 | $40,818,983 | +1.2% | 1,015,903 | +7.6% | 0.00% | 0.0% |
| Q1 2023 | $40,315,531 | -56.6% | 944,159 | -51.2% | 0.00% | -33.3% |
| Q4 2022 | $92,979,974 | +164.8% | 1,936,276 | +107.4% | 0.00% | +50.0% |
| Q3 2022 | $35,119,000 | +28.3% | 933,512 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $27,374,000 | -26.4% | 990,752 | +44.9% | 0.00% | 0.0% |
| Q1 2022 | $37,177,000 | -3.0% | 683,647 | +4.4% | 0.00% | 0.0% |
| Q4 2021 | $38,324,000 | +43.0% | 654,992 | -3.3% | 0.00% | +100.0% |
| Q3 2021 | $26,793,000 | -7.1% | 677,268 | -0.3% | 0.00% | -50.0% |
| Q2 2021 | $28,836,000 | -35.3% | 678,978 | -6.2% | 0.00% | -33.3% |
| Q1 2021 | $44,551,000 | +48.2% | 723,823 | +69.9% | 0.00% | +50.0% |
| Q4 2020 | $30,056,000 | +685.4% | 426,091 | +329.4% | 0.00% | – |
| Q3 2020 | $3,827,000 | +20.0% | 99,226 | +16.7% | 0.00% | – |
| Q2 2020 | $3,189,000 | – | 85,011 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 321,300 | $12,087,000 | 4.99% |
| First Light Asset Management, LLC | 598,213 | $22,505,000 | 2.28% |
| Nantahala Capital Management | 845,692 | $31,815,000 | 2.06% |
| CHI Advisors LLC | 200,229 | $7,533,000 | 2.03% |
| Fairmount Funds Management LLC | 272,498 | $10,251,000 | 1.80% |
| Altium Capital Management LP | 88,000 | $3,311,000 | 1.21% |
| Orbimed Advisors | 1,679,417 | $63,180,000 | 1.17% |
| SPHERA FUNDS MANAGEMENT LTD. | 206,819 | $7,781,000 | 1.08% |
| Parkman Healthcare Partners LLC | 99,927 | $3,759,000 | 1.07% |
| Soleus Capital Management, L.P. | 146,000 | $5,493,000 | 0.75% |